Scancell approved to raise dose on cancer vaccine trials

AIM-listed Scancell, the developer of therapeutic cancer vaccines, has announced that two key medical regulation bodies have given approval for a higher dose to be allowed in the company's latest trials on a vaccine to treat melanoma.

AIM-listed Scancell, the developer of therapeutic cancer vaccines, has announced that two key medical regulation bodies have given approval for a higher dose to be allowed in the company's latest trials on a vaccine to treat melanoma.

The Gene Therapy Advisory Committee and the Medicines and Healthcare Products Regulatory Agency's (MHRA) Medicines Division gave their approval for Scancell to dose an extra group of patients with a higher, 8 mg, dose of SCIB1, its DNA ImmunoBody vaccine being developed for the treatment of melanoma.

Scancell is planning to start treating patients with the 8mg dose in the new year.

This update follows the announcement made by Scancell on December 6th 2012, of preliminary results from Part 1 of the Phase 1/2 clinical trial of SCIB1 in patients with Stage III/IV malignant melanoma.

In view of the encouraging results and minimal side effects seen with the 4mg dose, the company stated that it intended to evaluate an 8mg dose in parallel with Part 2 of the Phase1/2 study.

Part 2 of the study continues to be on track to be completed by the end of 2013. A successful outcome, if achieved, would confirm the potential of SCIB1 as a new cancer treatment as well as validating the Immunobody platform technology.

Professor Lindy Durrant, Joint Chief Executive Officer of Scancell, commented: "This approval from GTAC and MHRA provides Scancell with the opportunity to determine whether a higher dose of SCIB1 would be even more effective in inducing immune response and clinical benefit in late stage melanoma patients."

Scancell's share price was up 2.06% to 49.50p at 12:26 on Wednesday afternoon.

MF

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

How the stamp duty holiday is pushing up house prices
Stamp duty

How the stamp duty holiday is pushing up house prices

Stamp duty is an awful tax and should be replaced by something better. But its temporary removal is driving up house prices, says Merryn Somerset Webb…
25 Sep 2020
Beware: even the greatest brands can fail
UK Economy

Beware: even the greatest brands can fail

For decades, John Lewis seemed to exist in a parallel universe. Now, a grimmer reality has dawned
27 Sep 2020
Can Rishi Sunak’s winter plan save the UK economy?
UK Economy

Can Rishi Sunak’s winter plan save the UK economy?

With his Winter Economic Plan, chancellor Rishi Sunak is hoping to support the economy through the dark months ahead as restrictions tighten again. Jo…
25 Sep 2020